“Bone metastases in castration-resistant prostate cancer (mCRPC) create a significant problem, Neal Shore, MD, medical director of the Carolina Urologic Research Institute, said in a recent presentation at the 2016 American Urological Association Annual Meeting.
” ‘A bone-metastatic event is really a seminal event,’ said Shore, who discussed the prevalence of bone metastases and possible preventative solutions. ‘It is quite an outstanding biologic and prognostic factor in mortality and, often times, in morbidity.’ ”
“Prostate cancer represents 21% of all new cancer cases in men and is the second most common cause of cancer death among American men after lung cancer, reported Shore.”
Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.